Acorda Therapeutics
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 471m | 192m | 153m | 129m | 119m | 118m | 139m |
| % growth | (20 %) | (59 %) | (20 %) | (16 %) | (8 %) | (1 %) | 18 % |
| EBITDA | 53.5m | 40.2m | (65.0m) | (44.8m) | (10.0m) | 9.0m | - |
| % EBITDA margin | 11 % | 21 % | (42 %) | (35 %) | (8 %) | 8 % | - |
| Profit | 33.7m | (273m) | (99.6m) | (104m) | (65.9m) | (253m) | - |
| % profit margin | 7 % | (142 %) | (65 %) | (81 %) | (56 %) | (215 %) | - |
| EV / revenue | 1.4x | 1.3x | 1.6x | 1.4x | 1.3x | - | - |
| EV / EBITDA | 12.5x | 6.1x | -3.6x | -3.9x | -15.3x | - | - |
| R&D budget | 106m | 60.1m | 23.0m | 10.4m | 5.8m | 5.2m | - |
| R&D % of revenue | 23 % | 31 % | 15 % | 8 % | 5 % | 4 % | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $1.3m | Series A | |
$100k | Grant | ||
| N/A | $2.0m | Grant | |
$400k | Grant | ||
$33.7m | Series A | ||
$6.0m | Series A | ||
$6.0m | Series B | ||
$55.3m | Series C | ||
| N/A | $11.5m | - | |
$490k | Grant | ||
| N/A | N/A | IPO | |
$19.0m | Post IPO Equity | ||
* | $185m Valuation: $185m 1.6x EV/LTM Revenues 20.6x EV/LTM EBITDA | Acquisition | |
* | N/A | N/A | Bankruptcy |
| Total Funding | CAD159m | ||
Related Content
Recent News about Acorda Therapeutics
EditAcorda Therapeutics, Inc. is a biotechnology company dedicated to developing and marketing therapies aimed at improving the lives of individuals with nervous system disorders. The company focuses on creating innovative treatments for conditions such as multiple sclerosis (MS) and Parkinson's disease. Acorda's primary clients include patients, healthcare professionals, and caregivers who are directly impacted by these neurological conditions.
Operating within the biotechnology and pharmaceutical market, Acorda leverages its extensive research and development expertise to bring new therapies from the lab to the market. The company has a robust pipeline of products, with notable therapies like AMPYRA, which helps improve walking in MS patients, and INBRIJA, an inhaled levodopa treatment for Parkinson's disease.
Acorda's business model revolves around the development, approval, and commercialization of its therapeutic products. The company invests heavily in research and clinical trials to ensure the efficacy and safety of its treatments. Once a product is approved by regulatory bodies, Acorda markets and sells these therapies to healthcare providers and directly to patients through various distribution channels.
Revenue generation for Acorda comes primarily from the sales of its approved therapies. Additionally, the company may receive milestone payments and royalties from partnerships and licensing agreements with other pharmaceutical companies. These collaborations help expand the reach of Acorda's products and bring in additional income streams.
In summary, Acorda Therapeutics is a biotechnology firm focused on developing and commercializing therapies for nervous system disorders, serving patients, healthcare professionals, and caregivers. The company operates in the biotech and pharmaceutical market, making money through product sales and strategic partnerships.
Keywords: biotechnology, nervous system disorders, therapies, multiple sclerosis, Parkinson's disease, AMPYRA, INBRIJA, research, commercialization, healthcare.
Tech stack
Investments by Acorda Therapeutics
Edit
